Venlafaxine Hydrochloride
"Venlafaxine Hydrochloride" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cyclohexanol and phenylethylamine derivative that functions as a SEROTONIN AND NORADRENALINE REUPTAKE INHIBITOR (SNRI) and is used as an ANTIDEPRESSIVE AGENT.
| Descriptor ID |
D000069470
|
| MeSH Number(s) |
D02.033.415.510.500.901 D02.092.471.683.948 D02.455.426.392.368.367.318.750 D10.289.510.500.901
|
| Concept/Terms |
Venlafaxine Hydrochloride- Venlafaxine Hydrochloride
- Hydrochloride, Venlafaxine
- Cyclohexanol, 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)-, hydrochloride
- 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)cyclohexanol HCl
Wy 45030- Wy 45030
- Wy-45030
- Wy45030
- Wy-45,030
- Wy 45,030
- Wy45,030
Effexor- Effexor
- Trevilor
- Vandral
- Efexor
|
Below are MeSH descriptors whose meaning is more general than "Venlafaxine Hydrochloride".
Below are MeSH descriptors whose meaning is more specific than "Venlafaxine Hydrochloride".
This graph shows the total number of publications written about "Venlafaxine Hydrochloride" by people in this website by year, and whether "Venlafaxine Hydrochloride" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 2 | 1 | 3 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 1 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Venlafaxine Hydrochloride" by people in Profiles.
-
Effect of augmentation with aripiprazole or augmentation with repetitive transcranial magnetic stimulation versus switching to the antidepressant venlafaxine extended release/duloxetine on cognition: A comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD). J Affect Disord. 2025 Dec 01; 390:119836.
-
Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial. Mol Psychiatry. 2024 Aug; 29(8):2287-2295.
-
Longitudinal Neurocognitive Effects of Combined Electroconvulsive Therapy (ECT) and Pharmacotherapy in Major Depressive Disorder in Older Adults: Phase 2 of the PRIDE Study. Am J Geriatr Psychiatry. 2022 01; 30(1):15-28.
-
Multinational Investigation of Fracture Risk with Antidepressant Use by Class, Drug, and Indication. J Am Geriatr Soc. 2020 07; 68(7):1494-1503.
-
Neurocognitive Effects of Combined Electroconvulsive Therapy (ECT) and Venlafaxine in Geriatric Depression: Phase 1 of the PRIDE Study. Am J Geriatr Psychiatry. 2020 03; 28(3):304-316.
-
Effect of Problem-Solving Therapy Versus Supportive Management in Older Adults with Low Back Pain and Depression While on Antidepressant Pharmacotherapy. Am J Geriatr Psychiatry. 2018 07; 26(7):765-777.
-
Effects of a Course of Right Unilateral Ultrabrief Pulse Electroconvulsive Therapy Combined With Venlafaxine on Insomnia Symptoms in Elderly Depressed Patients. J Clin Psychiatry. 2018 Mar/Apr; 79(2).
-
Effects of continuation electroconvulsive therapy on quality of life in elderly depressed patients: A randomized clinical trial. J Psychiatr Res. 2018 02; 97:65-69.
-
Association of QT-Prolonging Medication Use in CKD with Electrocardiographic Manifestations. Clin J Am Soc Nephrol. 2017 09 07; 12(9):1409-1417.
-
Right Unilateral Ultrabrief Pulse ECT in Geriatric Depression: Phase 1 of the PRIDE Study. Am J Psychiatry. 2016 Nov 01; 173(11):1101-1109.